Agios Pharmaceuticals, Inc. (AGIO)
🔔 Watch stock
Stock Watch
Stock Watch will tell you what changes at Agios Pharmaceuticals, Inc..
Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.
Appears in These Scanners
This stock currently matches 8 of our scanner strategies — each hit links to the scanner.
Only genuine hits from verified scanners count; pure ranking metrics (P/E, P/S, and similar, which just sort the whole universe) don't count as a hit. Scanners marked in red are red-flag signals (risk/short scanners) — appearing there is not a seal of approval. View all scanners
Trading Day
Key levels of the most recently completed trading day — not a live quote.
52-Week Range
Current price 30.50 $ — 35% of the range above the low.
Lowest and highest closing price over the last 52 weeks. The marker shows where the current price sits within that range: close to the high speaks for strength, close to the low for weakness.
Basics
Performance
Technical Indicators
Calculated from the price history · as of 08/04/2026
Valuation
Profitability
Balance Sheet & Safety
Growth
Dividend
This stock currently pays no dividend.
Quality & Screener
AAQS
4/10The AAQS (AlleAktien Quality Score) checks 10 quality criteria on growth, profitability, and balance-sheet strength — per the methodology developed and published by AlleAktien, calculated by us from our own fundamental data. A stock counts as a quality stock from 9 out of 10 points. Where a company has a shorter listing history, we calculate over the fiscal years available (at least five).
- Sales growth 10Y > 5% -2.8%
- Exp. sales growth 3Y > 5% 146.9%
- EBIT growth 10Y > 5% –
- Exp. EBIT growth 3Y > 5% 146.9%
- Net debt < 4x EBIT –
- EBIT positive, 10Y straight 0
- Max. EBIT decline < 50% –
- Return on equity > 15% -34.6%
- ROCE > 15% -38.9%
- Expected return > 10% 94.9%
View all AAQS quality stocks · Read the methodology at AlleAktien
Source: fundamental data
AI Rating
–Not yet rated — we only show a category once an SEC-backed file with at least two cited passages is available. How the Rating Is Built
Growth Score
6 of 10 Solid growthTen checks against the annual reports — each one passed counts a point.
- Revenue grows by more than 15% a year over three years 56.0% passed
- More than 10% revenue growth is expected for the coming year 110.6% passed
- Share count grows by less than 3% a year 1.9% passed
- Revenue growth plus cash-flow margin add up to at least 40 ("Rule of 40") -650.3% failed
- Gross margin at 40% or higher and without meaningful erosion 78.7% passed
- Goodwill from acquisitions does not grow faster than revenue 0.0% passed
- Net debt below twice EBITDA 814 m net cash passed
- Operating cash flow covers the profits of the last three years -968 m failed
- Return on capital at 15% or higher, or up versus two years ago -38.9% failed
- Insiders hold at least 10% or are net buyers 1.1% failed
A criterion without figures counts neither as passed nor as failed; a score is only produced from 7 judgeable criteria upwards. Source: fundamental data. All ten criteria in detail
Highlighted are things our editorial team noticed: green = stands out as strong, red = deserves a closer look. No single metric is a verdict on its own — always read it in context.
Analysts & Price Target
The price target sits 48.8% above the current price.
- Consensus
- Sell
- Analyst Ratings
- 9
Combined picture of the price targets and recommendations of every analyst covering the stock. Price targets are expectations for the next 12 months, not promises — and they often follow the price rather than predict it.
Estimates by Fiscal Year
| Fiscal Year | EPS Estimate ($) | EPS Range ($) | Revenue Estimate ($M) | Expected Growth | Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | -5.66 | -6.49 – -4.75 | 179 | 20.5% | 7 |
| 12/31/2027 | -4.03 | -5.06 – -2.12 | 329 | 24.0% | 9 |
Average of the analyst estimates for the coming fiscal years. The range shows how far the most optimistic and the most cautious estimate sit apart — the wider it is, the less certain the expectation.
Revenue & Profit
Cash Flow
Balance Sheet
Margins
Per Share
Click the chart or tab into it, then use ← and → to step through the periods.
None of the selected stocks reports this metric. Pick another metric or switch between annual and quarterly.
· Total · per year
These companies report in different currencies — switch on “Indexed” or pick a margin for a fair comparison.
The figures could not be loaded right now.
Source: fundamental data
Quarterly Figures
| Quarter | EPS (Earnings Per Share) | EPS YoY (%) | Sales ($M) | Sales YoY (%) | Net Margin (%) | OCF ($M) | FCF ($M) |
|---|---|---|---|---|---|---|---|
| 2024: Q4 | -1.69 | – | 11 | 51.10 | -899.60 | -133 | -134 |
| 2025: Q1 | -1.55 | – | 9 | 6.60 | -1,023.30 | -112 | -112 |
| 2025: Q2 | -1.93 | – | 13 | 44.60 | -899.40 | -77 | -78 |
| 2025: Q3 | -1.78 | -111.00 | 13 | 43.70 | -803.10 | -88 | -90 |
| 2025: Q4 | -1.85 | – | 20 | 86.10 | -541.10 | -96 | -97 |
| 2026: Q1 | -1.69 | – | 21 | 137.70 | -477.70 | -119 | -120 |
| 2026: Q2 | -1.69 | 12.40 | 45 | 257.60 | -225.30 | -57 | -59 |
- EPS (Earnings Per Share):
- Quarterly profit divided by the total share count — how much of the profit works out to a single share.
- YoY (Year over Year):
- Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
- Sales:
- All revenue for the quarter, before any costs are deducted — the top line of the income statement.
- Net Margin:
- What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
- OCF (Operating Cash Flow):
- The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
- FCF (Free Cash Flow):
- Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.
Annual Figures
| Fiscal Year | Revenue ($M) | EBIT ($M) | Net Income ($M) | EPS ($) | Operating Cash Flow ($M) | Equity ($M) | Total Assets ($M) |
|---|---|---|---|---|---|---|---|
| 2016 | 70 | -201 | -198 | -5.07 | 39 | 359 | 619 |
| 2017 | 43 | -321 | -315 | -6.75 | -285 | 376 | 614 |
| 2018 | 94 | -362 | -346 | -6.03 | -304 | 688 | 858 |
| 2019 | 118 | -426 | -411 | -6.86 | -371 | 641 | 891 |
| 2020 | 203 | -336 | -327 | -4.74 | -291 | 400 | 853 |
| 2021 | 0 | -378 | 1,605 | 26.55 | -407 | 1,292 | 1,438 |
| 2022 | 14 | -389 | -232 | -4.23 | -309 | 1,101 | 1,239 |
| 2023 | 27 | -391 | -352 | -6.33 | -296 | 811 | 937 |
| 2024 | 37 | -426 | 674 | 11.64 | -390 | 1,541 | 1,663 |
| 2025 | 54 | -472 | -413 | -7.12 | -373 | 1,193 | 1,297 |
Fiscal years from the audited annual reports, oldest first. EBIT is the operating profit before interest and taxes; total assets are everything the company owns.
About the Company
Agios Pharmaceuticals, Inc., ein biopharmazeutisches Unternehmen, entdeckt und entwickelt Medikamente im Bereich des Zellstoffwechsels in den USA.
| CEO Insider Trades (12 Mo.) | selling own stock |
|---|---|
| Employees | 539 |
| Headquarters | Cambridge, MA |
| Address | 88 Sidney Street, 02139 Cambridge, United States |
| Phone | 617 649 8600 |
| Website | agios.com |
| IPO Date | 24. Jul 2013 |
| ISIN | US00847X1046 |
Management
| Name | Title | Birth Year |
|---|---|---|
| Brian M. Goff M.B.A. | CEO & Director | 1969 |
| Cecilia Jones | Chief Financial Officer | 1975 |
| Krishnan Viswanadhan M.B.A., Pharm.D. | Chief Strategy & Operations Officer | 1979 |
| James William Burns | Chief Legal Officer | 1978 |
| Sarah Gheuens M.D., Ph.D. | Chief Medical Officer and Head of Research & Development | 1980 |
| Lewis clayton Cantley Ph.D. | Co-Founder | 1949 |
| Tak Wah Mak D.Sc., FRSC, Ph.D. | Co-Founder | 1946 |
| Craig B. Thompson M.D. | Co-Founder | 1953 |
| Shin-San Su Ph.D. | Co-Founder | 1956 |
| T. J. Washburn | VP, Controller & Principal Accounting Officer | 1982 |
Executives per the latest required filings; titles kept in their original language. Source: fundamental data.
Chart
Interactive price chart (TradingView).
Data as of: August 3, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.